HISTOPATHOLOGICAL AND IMMUNOCHEMICAL CHARACTERISTICS OF GASTROINTESTINAL NEUROENDOCRINOMA ACCORDING TO THE 2022 WHO CLASSIFICATION AT BACH MAI HOSPITAL

Thị Yến Trần, Trung Thọ Lê, Văn Tuyến Phạm, Thị Duyên Hoàng

Main Article Content

Abstract

Purpose: Determine the rate of immunohistochemical markers of neuroendocrine tumors (NEUs) according to the WHO 2022. Methods: A Cross-sectional description on 67 patients diagnosed with gastrointestinal neuroendocrine tumors at Bach Mai Hospital from 2020 to 2025. Results: The male/female ratio is 1.4/1. The average age of onset is 52.99±15.7. Neuroendocrine tumors are mainly found in the rectum, accounting for 46.3%. The most common tumor tissue structure is mixed trabecular and solid. The main histological grade is grade 1. The immunohistochemical expression rate is high. Synaptophysin is almost completely expressed at a rate of 98.5%, followed by Chromogranin A at a rate of 77.6%, and CD56 is positive at 43.3%. The Ki67 positive rate varies and Ki67 positive at a rate of <3% is the highest, accounting for 82.1%. Conclution: In neuroendocrine tumors, immunohistochemical markers are used for the definitive diagnosis and histological grade in neuroendocrine tumors. Expression of Synaptophysin, Chromogranin A and CD56 is significant in the definitive diagnosis while high Ki 67 ratio is significant in the histological grade diagnosis in neuroendocrine tumors. High histological grade is a poor prognostic factor, increasing the rate of metastasis in neuroendocrine tumors.

Article Details

References

Lawrence, B. et al. The epidemiology of gastroenteropancreatic neuroendocrine tumors. Endocrinol Metab Clin North Am 40, 1–18, vii (2011).
2. Baloch, Z. W. et al. Overview of the 2022 WHO Classification of Thyroid Neoplasms. Endocr Pathol 33, 27–63 (2022).
3. Ahmed, M. Gastrointestinal neuroendocrine tumors in 2020. World Journal of Gastrointestinal Oncology 12, 791 (2020).
4. Ahmed, M. Gastrointestinal neuroendocrine tumors in 2020. World J Gastrointest Oncol 12, 791–807 (2020).
5. Popa, O. et al. The new WHO classification of gastrointestinal neuroendocrine tumors and immunohistochemical expression of somatostatin receptor 2 and 5. Exp Ther Med 22, 1179 (2021).